A reactive oxygen species scoring system predicts cisplatin sensitivity and prognosis in ovarian cancer patients

Sun, Chaoyang; Guo, Ensong; Zhou, Bo; Shan, Wanying; Huang, Jia; Weng, Danhui; Wu, Peng; Wang, Changyu; Wang, Shixuan; Zhang, Wei; Gao, Qinglei; Xu, Xiaoyan; Wang, Beibei; Hu, Junbo; Ma, Ding; Chen, Gang

doi:10.1186/s12885-019-6288-7

Cited by 21 publications

(17 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Prediction of treatment responses makes sense for HGSOC [10]. For HGSOC patients, treatment regimens are scheduled based on platinum sensitivity [37,38]. However, nearly 20% of patients are inherently resistant to platinum agents [1].…”

Section: Discussionmentioning

confidence: 99%

“…Moreover, improper platinum dosage is toxic and may import resistance to other drugs [3,4]. Some gene profile-based techniques combined with sequencing, microarrays, and PCR were developed to predict prognosis and drug responsiveness of ovarian cancer, but their application had limitations [38,39]. Moreover, detection of protein expression can be more effective than gene screening.…”

Section: Discussionmentioning

confidence: 99%

“…Nearly all HGSOC patients will receive platinum-containing regimens as the first-line treatment option [1,4]. However, without pre-determination of platinum responsiveness, 30% of patients have undergone multiple rounds of useless and even toxic treatment [5]. As a highly deadly and heterogeneous disease, subtype-specific biomarkers for the large group of HGSOC patients are urgently needed [6].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Expression of hormone receptors predicts survival and platinum sensitivity of high-grade serous ovarian cancer

et al. 2021

Self Cite

View full text Add to dashboard Cite

High-grade serous ovarian cancer (HGSOC) has abundant expression of hormone receptors, including androgen receptor (AR), estrogen receptor α (ER), and progesterone receptor (PR). The effects of hormone receptors on prognosis of HGSOC were first evaluated in online databases. Their prognostic values were then explored and validated in our inhouse TJ-cohort (92 HGSOC patients) and in a validation cohort (33 HGSOC patients), wherein hormone receptors were detected immunohistochemically. High expression of hormone receptors denoted longer progression-free survival (PFS), overall survival (OS), and platinum-free interval (PFI). Platinum-sensitive patients had higher expression of hormone receptors than their counterparts. Correlation analysis revealed significant positive correlations between hormone receptors expression and survival. AR, ER, and PR had predictive and prognostic values, alone and in combination. By receiver operating characteristic curve (ROC) analysis, co-expression of AR, ER, and PR had an improved predictive performance with an area under the curve (AUC) value of 0.945. Expression of hormone receptors predicts survival and platinum sensitivity of HGSOC. AR, ER, and PR might be feasible prognostic biomarkers for HGSOC by immunohistochemical analysis.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Expression of hormone receptors predicts survival and platinum sensitivity of high-grade serous ovarian cancer

et al. 2021

Self Cite

View full text Add to dashboard Cite

show abstract

“…In this system, there are 25 scores in which scores 0-12 demonstrate low score groups, while scores 13-25 show high score groups. As ROS overgeneration enhances CP sensitivity and apoptosis induction, by enhancing ROS levels, patients are included in high score groups, which have high overall survival and good prognosis [102]. This score can be used in clinical course.…”

Section: Ros Cisplatin Chemotherapy and Related Molecular Pathways Cisplatin Sensitivitymentioning

confidence: 99%

Elucidating Role of Reactive Oxygen Species (ROS) in Cisplatin Chemotherapy: A Focus on Molecular Pathways and Possible Therapeutic Strategies

et al. 2021

View full text Add to dashboard Cite

The failure of chemotherapy is a major challenge nowadays, and in order to ensure effective treatment of cancer patients, it is of great importance to reveal the molecular pathways and mechanisms involved in chemoresistance. Cisplatin (CP) is a platinum-containing drug with anti-tumor activity against different cancers in both pre-clinical and clinical studies. However, drug resistance has restricted its potential in the treatment of cancer patients. CP can promote levels of free radicals, particularly reactive oxygen species (ROS) to induce cell death. Due to the double-edged sword role of ROS in cancer as a pro-survival or pro-death mechanism, ROS can result in CP resistance. In the present review, association of ROS with CP sensitivity/resistance is discussed, and in particular, how molecular pathways, both upstream and downstream targets, can affect the response of cancer cells to CP chemotherapy. Furthermore, anti-tumor compounds, such as curcumin, emodin, chloroquine that regulate ROS and related molecular pathways in increasing CP sensitivity are described. Nanoparticles can provide co-delivery of CP with anti-tumor agents and by mediating photodynamic therapy, and induce ROS overgeneration to trigger CP sensitivity. Genetic tools, such as small interfering RNA (siRNA) can down-regulate molecular pathways such as HIF-1α and Nrf2 to promote ROS levels, leading to CP sensitivity. Considering the relationship between ROS and CP chemotherapy, and translating these findings to clinic can pave the way for effective treatment of cancer patients.

show abstract

“…Accurate reactive oxygen species (ROS) quantification and characterization plays an important role in the investigation of metabolism [1,2], inflammatory responses [3,4], the pathogenesis of the disease [5,6], treatment monitoring [7][8][9] [10] and potentially provides prognostic information [11]. Currently, standard ROS measurement uses various molecular indicators such as dichlorofluorescein, a fluorescent probe that reacts intracellularly with peroxidase, or CellROX, a fluorogenic probe for measuring oxidative stress in live cells and tissue [12][13][14].…”

Section: Introductionmentioning

confidence: 99%

Non-invasive real-time imaging of reactive oxygen species (ROS) using multispectral auto-fluorescence imaging technique: a novel tool for redox biology

Habibalahi¹,

Moghari

Campbell

et al. 2020

Preprint

View full text Add to dashboard Cite

AbstractDetecting reactive oxygen species (ROS) that play a critical role as redox modulators and signalling molecules in biological systems currently requires invasive methods such as ROS - specific indicators for imaging and quantification. We developed a non-invasive, real-time, label-free imaging technique for assessing the level of ROS in live cells and thawed cryopreserved tissues that is compatible with in-vivo imaging. The technique is based on autofluorescence multispectral imaging (AFMI) carried out in an adapted fluorescence microscope with an expanded number of spectral channels spanning specific excitation (365 nm-495 nm) and emission (420 nm-700 nm) wavelength ranges. We established a strong quantitative correlation between the spectral information obtained from AFMI and the level of ROS obtained from CellROX staining. The results were obtained in several cell types (HeLa, PANC1 and mesenchymal stem cells) and in live kidney tissue. Additioanly, two spectral regimes were considered: with and without UV excitation (wavelengths > 400 nm); the latter being suitable for UV-sensitive systems such as the eye. Data were analyzed by linear regression combined with an optimization method of swarm intelligence. This allowed the calibration of AFMI signals to the level of ROS with excellent correlation (R= 0.84, p=0.00) in the entire spectral range and very good correlation (R= 0.78, p=0.00) in the limited, UV-free spectral range. We also developed a strong classifier which allowed us to distinguish moderate and high levels of ROS in these two regimes (AUC= 0.91 in the entire spectral range and AUC = 0.78 for UV-free imaging). These results indicate that ROS in cells and tissues can be imaged non-invasively, which opens the way to future clinical applications in conditions where reactive oxygen species are known to contribute to progressive disease such as in ophthalmology, diabetes, kidney disease, cancer and neurodegenerative diseases.

show abstract

A reactive oxygen species scoring system predicts cisplatin sensitivity and prognosis in ovarian cancer patients

Cited by 21 publications

References 35 publications

Expression of hormone receptors predicts survival and platinum sensitivity of high-grade serous ovarian cancer

Expression of hormone receptors predicts survival and platinum sensitivity of high-grade serous ovarian cancer

Elucidating Role of Reactive Oxygen Species (ROS) in Cisplatin Chemotherapy: A Focus on Molecular Pathways and Possible Therapeutic Strategies

Non-invasive real-time imaging of reactive oxygen species (ROS) using multispectral auto-fluorescence imaging technique: a novel tool for redox biology

Contact Info

Product

Resources

About